Zydus receives final approval from USFDA for Prucalopride Tablets

Prucalopride is prescribed for chronic idiopathic constipation

Akums reports Q1 FY26 PAT at Rs. 65 Cr

During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals

Cupid Q1 FY26 PAT jumps 82% at Rs. 15 Cr

Cupid reported total income of Rs. 64.75 crore in Q1 FY26 as compared to Rs. 44.03 crore in Q1 Fy25

Suraksha Diagnostic reports Q1 FY26 PAT higher by 20% at Rs. 9.1 Cr

Hikal reports Q1 FY26 consolidated loss of Rs. 22.4 Cr

Hikal has reported total income of Rs. 381.4 crores during the period ended June 30, 2025

Sigachi begins construction work for MCC capacity expansion at Dahej

With this addition, the company’s total Installed MCC Capacity will rise to 30,000 MTPA

Metropolis Healthcare reports Q1 FY26 PAT higher by 19% at Rs. 45 Cr

Quest Diagnostics completes acquisition of Spectra Laboratories’ Clinical Testing Assets from Fresenius Medical Care

Quest will now offer dialysis-related clinical testing services to independent dialysis clinics

Caplin Point Laboratories posts Q1 FY26 consolidated PAT at Rs. 152.80 Cr

Caplin Point Laboratories has reported total income of Rs. 533.36 crores during the period ended June 30, 2025

ZIM Laboratories granted marketing authorization for Tamsulosin + Dutasteride capsules in Australia

Tamsulosin, an alpha-1 adrenergic receptor blocker, combined with Dutasteride, a dual 5- alpha-reductase inhibitor, is indicated for the treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH) in adult men